Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

Visa's stock closed more than 5% lower for the day. Senators grilled Novo Nordisk CEO Lars Fruergaard Jørgensen at a hearing on Tuesday over the high prices of the company's blockbuster injections.

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's ...

While Congress debates the high cost of brand-name diabetes and weight loss drugs, Atlanta doctors are selling lower-cost alternatives made by compounding pharmacies.

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised Tuesday to examine lowering their prices in the United States, after ...

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But ...

The head of Ozempic manufacturer Novo Nordisk on Tuesday defended the high price of the company’s highly sought-after obesity and Type 2 diabetes drugs, blaming pharma middlemen ...